{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T14:40:09Z","timestamp":1732286409607,"version":"3.28.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.leukres.2024.107599","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:27:20Z","timestamp":1730107640000},"page":"107599","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology"],"prefix":"10.1016","volume":"147","author":[{"given":"Josefine","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Blau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Bettelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Bocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Nogai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107599_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.leukres.2024.107599_bib2","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107599_bib3","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107599_bib4","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/bloodadvances.2019000122","article-title":"Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression","volume":"4","author":"Walker","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107599_bib5","first-page":"1","article-title":"Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma","volume":"2023","author":"Kropivsek","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.leukres.2024.107599_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-3613","article-title":"Abstract 3613: lab-on-a-chip-based in-vitro functional profiling proves to be effective in predicting therapy outcome in AML patients","volume":"78","author":"Rocchi","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2024.107599_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cyto.2012.01.012","article-title":"Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts","volume":"58","author":"Rellick","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.leukres.2024.107599_bib8","first-page":"597","article-title":"The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone","volume":"26","author":"Grigorieva","year":"1998","journal-title":"Exp. Hematol."},{"issue":"1979","key":"10.1016\/j.leukres.2024.107599_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.leukres.2024.107599_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107599_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti\u2013multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107599_bib12","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2024.107599_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107599_bib14","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107599_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2024.107599_bib16","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2021-151922","article-title":"Immune profiles of myeloma tumor microenvironment may predict sensitivity or resistance to elotuzumab","volume":"138","author":"Noyes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107599_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2024.107599_bib18","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1182\/blood-2019-126894","article-title":"Inter-cell networking profiling enables comprehensive characterization of immune-mediated activity of anti-CD38 Therapy through ex-vivo analysis of multiple myeloma patients","volume":"134","author":"Bettelli","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107599_bib19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.V128.22.1675.1675","article-title":"Ex-Vivo drug response profiling for precision medicine approaches in acute myeloid leukemia with the open microwell microfluidic platform","volume":"128","author":"Rocchi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107599_bib20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107599_bib21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107599_bib22","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.leukres.2024.107599_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.leukres.2024.107599_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00432-021-03854-6","article-title":"Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma","volume":"148","author":"Waldschmidt","year":"2022","journal-title":"J. Cancer Res Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T14:16:08Z","timestamp":1732198568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"alternative-id":["S0145212624001656"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107599","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107599"}}